Heike Wulff

Affiliations: 
Chemistry University of California, Davis, Davis, CA 
Area:
Organic Chemistry, Medicine and Surgery
Google:
"Heike Wulff"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Jin LW, Lucente JD, Nguyen HM, et al. (2019) Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease. Annals of Clinical and Translational Neurology. 6: 723-738
Di Lucente J, Nguyen HM, Wulff H, et al. (2018) The voltage-gated potassium channel Kv1.3 is required for microglial pro-inflammatory activation in vivo. Glia
Slavi N, Toychiev AH, Kosmidis S, et al. (2018) Suppression of connexin 43 phosphorylation promotes astrocyte survival and vascular regeneration in proliferative retinopathy. Proceedings of the National Academy of Sciences of the United States of America
Chen YJ, Nguyen HM, Maezawa I, et al. (2018) Inhibition of the potassium channel Kv1.3 reduces infarction and inflammation in ischemic stroke. Annals of Clinical and Translational Neurology. 5: 147-161
Maezawa I, Nguyen HM, Di Lucente J, et al. (2017) Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept. Brain : a Journal of Neurology
Nguyen HM, Singh V, Pressly B, et al. (2017) Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore. Molecular Pharmacology
Hilt S, Tang T, Walton JH, et al. (2016) A Metal-Free Method for Producing MRI Contrast at Amyloid-β. Journal of Alzheimer's Disease : Jad
Nguyen HM, Grössinger EM, Horiuchi M, et al. (2016) Differential Kv1.3, KCa3.1, and Kir2.1 expression in "classically" and "alternatively" activated microglia. Glia
Pessah IN, Rogawski MA, Tancredi DJ, et al. (2016) Models to identify treatments for the acute and persistent effects of seizure-inducing chemical threat agents. Annals of the New York Academy of Sciences
Glaser N, Little C, Lo W, et al. (2016) Treatment with the KCa3.1 inhibitor TRAM-34 during diabetic ketoacidosis reduces inflammatory changes in the brain. Pediatric Diabetes
See more...